Revolutionary Approach
One Breakthrough Could Change Everything
One Pill, Multiple Life Changing Opportunities.
More Chances
for Success, Greater Potential for Investors.
Trethera stands at the cutting edge of innovation, tackling some of the world’s toughest diseases—with a groundbreaking drug and a team of proven experts. Our Reg CF offering allows you to join us in accelerating this life-saving mission.
One Investment, Multiple Opportunities To Succeed
Investing in Trethera means backing a diversified approach to treating complex diseases. From ADEM, optic neuritis, MS, cancer, lupus, and Crohn’s, each successful milestone brings us closer to making a tangible difference for patients and generating meaningful returns.
Broad Uses
TRE-515 is a first-in-class therapy aimed at treating ADEM, optic neuritis, MS, cancer, lupus, Crohn’s and more —offering investors a unique, diversified opportunity within a single drug.
More Shots on Goal
Each clinical trial we conduct opens new doors for success, with each disease indication creating multiple pathways to impact.
Win on One, Win Big
A single approved indication has massive market potential (at least $500M), creating significant opportunities for investors. Even one success is an entire business in itself.
Reduced Risk
Our multi-indication strategy decreases risk by broadening the scope of our development across various high-impact diseases – and already treating cancer patients in clinical trials.
One Pill, One Solution,
Multiple Implications.
Introducing TRE-515 – A groundbreaking, well tolerated, therapy targeting multiple diseases.
Many patients with cancer and autoimmune diseases face limited treatment options with severe side effects. TRE-515 is designed to potentially offer a safer, more effective solution, targeting diseases at their root.
Trethera is leading the way by focusing on the salvage pathway—a key metabolic process essential for the growth of diseased cells in cancers, autoimmune diseases, and inflammatory disorders.
The salvage pathway is a process used by bad-acting, abnormal cells, particularly those that divide rapidly (like cancer and autoimmune cells), to produce essentials for growth.
TRE-515 selectively blocks an enzyme in this pathway called dCK (that has never been blocked before) and stops these harmful cells while sparing healthy ones. Like a bodyguard, for your body.
In this video, observe the dramatic difference that TRE-515 makes in the fight against Multiple Sclerosis (MS). Mice treated with TRE-515 show remarkable improvement, flourishing despite the initial disease, while untreated mice deteriorate rapidly. This powerful visual highlights the potential of TRE-515 to change the course of treatment for complex diseases—offering hope for better outcomes with fewer side effects.
Revolutionary Approach
Our Revolutionary Solution
TRE-515 effectively blocks the salvage pathway to target harmful cells, and prevent them from growing while potentially minimizing side effects— a significant leap in patient care.
By selectively inhibiting this pathway, TRE-515 is designed to potentially offer patients a targeted treatment that shrinks tumors, restores immune balance, and improves quality of life with fewer side effects.
First-in-Class Therapy:
TRE-515 uniquely targets a disease progression pathway while sparing healthy cells.
Multiple Indications:
TRE-515’s broad therapeutic potential spans MS, cancer, lupus, and Crohn’s disease.
Limited Side Effects:
By focusing on diseased cells, TRE-515 can potentially have superior safety.
Promising Science:
With encouraging results from preclinical and early clinical studies, TRE-515 is well-positioned to transform treatment options.
Your investment could be the key to giving hope and transforming lives for millions.Your investment supports the advancement of TRE-515, potentially saving lives and changing the landscape for difficult-to-treat diseases.
Accelerating Clinical Trials: Your support pushes forward clinical trials, moving TRE-515 closer to FDA approval.
Tackling Multiple Diseases: A single drug addressing multiple diseases amplifies the potential for success and impact.
Bridging the Gap: Your investment helps bring life-saving treatments to patients faster.
Access for All: Supporting our Reg CF campaign ensures TRE-515 reaches diverse populations, from urban centers to rural communities.
Trethera is Already Making Life-Changing Strides
378% Company Value Growth
Since 2021, Trethera’s internal valuation has surged through scientific breakthroughs and strategic investment.
Over $7 Million in NIH Grants
NIH funding matches investor contributions, reducing financial risk for investors – these grants have no payback, and are not considered a loan.
Patent Protection
Among the patents Trethera holds, TRE-515 is patented to at least 2041, securing exclusive market rights. Several patents have been issued and granted by the USPTO.
FDA authorization, NIH Support and Orphan Drug Status:
The FDA and NIH have recognized TRE-515 achievements. The orphan drug status grants 7 years of market exclusivity, a $4M fee waiver, and tax incentives for autoimmune indications.
Be Part of the Next Big Biotech Breakthrough
Join Us in Changing the Future of Disease Treatment Accelerate the journey of life-saving treatments.
Next Big Biotech Breakthrough
Clinical Trials
Fund Phase 1 dose trials to finalize optimal dosage for disease indications.
Additional Mouse Studies
Evaluate TRE-515’s effects on MS, lupus, and Crohn’s disease. Further evaluate other cancers and autoimmune diseases.
Regulatory Approvals
Engage with the FDA to start additional clinical trials.
Scale Manufacturing
We will use part of the funds to manufacture 10 pounds of TRE-515.
Patent Filings
Protect global patent rights for commercialization that provide TRE-515 market exclusivity until 2041 and beyond.
Team Expansion
Add research and science staff to accelerate development.
Bringing TRE-515 to Patients and Creating Value for Investors
Kenneth Schultz, MD
Chairman, CEO, & President
Previous leadership roles at Halozyme, Medtronic, and McKinsey & Company.
Cary Talbot
Chief Operating Officer
Previous leadership roles at Medtronic and Hughes Aircraft.
Evelina Rubinchik, PHD
Preclinical Development
Previous leadership roles at Migenix and Micrologix.
Joyce James, PHD
Clinical Pharmacology
Previous leadership roles at Lyric, Cytokinetics, and Merck.
Chris Santos
Manufacturing
Previous leadership roles at Illumina, Kalypsys, and Victory.
